Fosigotifator by Calico Life Sciences for Unspecified Central Nervous System Disorders: Likelihood of Approval

Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders.

Inline, real-time PAT tool is a game-changer for pharma granulation sector – Pharmaceutical Technology

Credit: Shutterstock Drug shortages worldwide are worsening due to increased demand for high-quality manufacturing capacity in the pharmaceutical industry. Short-term contingency plans from healthcare providers

June 3, 2024

Introducing the Psychedelic News Feed – Psychedelic Alpha

I’m excited to share our latest free feature: The Psychedelic News Feed. This webpage aims to serve as a one-stop destination for the latest media

October 10, 2023

Gilgamesh Scoops $14m from NIDA to Develop Safer Ibogaine Analog for Opioid Use Disorder – Psychedelic Alpha

Psychedelic drug developer Gilgamesh Pharmaceuticals has scooped a grant worth $14m from the National Institute on Drug Abuse (NIDA) to develop its ibogaine analog, GM-3009,

March 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.